Modified monoclonal antibodies such as Bevacizumab, in turn, can attach to enzymes or growth factors necessary for cancer cell growth, such as vascular endothelial growth factor (VEGF), thereby inhibiting neovascularization and tumor expansion [8]. This evidence concerns the gene VEGFA and cancer.